| dc.contributor.author |
Zalutsky, MR |
|
| dc.coverage.spatial |
England |
|
| dc.date.accessioned |
2015-12-03T18:30:42Z |
|
| dc.date.issued |
2004-04-19 |
|
| dc.identifier |
https://www.ncbi.nlm.nih.gov/pubmed/15083170 |
|
| dc.identifier |
6601771 |
|
| dc.identifier.issn |
0007-0920 |
|
| dc.identifier.uri |
https://hdl.handle.net/10161/11048 |
|
| dc.description.abstract |
The utility of external beam radiotherapy for the treatment of malignant brain tumours
is compromised by the need to avoid excessive radiation damage to normal CNS tissues.
This review describes the current status of targeted radiotherapy, an alternative
strategy for brain tumour treatment that offers the exciting prospect of increasing
the specificity of tumour cell irradiation.
|
|
| dc.language |
eng |
|
| dc.publisher |
Springer Science and Business Media LLC |
|
| dc.relation.ispartof |
Br J Cancer |
|
| dc.relation.isversionof |
10.1038/sj.bjc.6601771 |
|
| dc.subject |
Antibodies, Monoclonal |
|
| dc.subject |
Astrocytoma |
|
| dc.subject |
Brain Neoplasms |
|
| dc.subject |
Clinical Trials as Topic |
|
| dc.subject |
Glioblastoma |
|
| dc.subject |
Humans |
|
| dc.subject |
Radiation Injuries |
|
| dc.subject |
Radioimmunotherapy |
|
| dc.title |
Targeted radiotherapy of brain tumours. |
|
| dc.type |
Journal article |
|
| duke.contributor.id |
Zalutsky, MR|0095795 |
|
| pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/15083170 |
|
| pubs.begin-page |
1469 |
|
| pubs.end-page |
1473 |
|
| pubs.issue |
8 |
|
| pubs.organisational-group |
Clinical Science Departments |
|
| pubs.organisational-group |
Duke |
|
| pubs.organisational-group |
Duke Cancer Institute |
|
| pubs.organisational-group |
Institutes and Centers |
|
| pubs.organisational-group |
Pathology |
|
| pubs.organisational-group |
Radiation Oncology |
|
| pubs.organisational-group |
Radiology |
|
| pubs.organisational-group |
School of Medicine |
|
| pubs.publication-status |
Published |
|
| pubs.volume |
90 |
|
